ArticleBJPsych open2024
Care pathways, prescribing practices and treatment outcomes in major depressive disorder and treatment-resistant depression: retrospective, population-based cohort study.
Article in BJPsych open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs.Psychopharmacology · 2025Pooled it
- Trajectory of response to esketamine nasal spray for treatment resistant depression: Findings from ESCAPE-TRD.European psychiatry : the journal of the Association of European Psychiatrists · 2026Trial
- Medicinal Plants for Major Depressive Disorder.Brain sciences · 2026Review
- Examining the needs, outcomes and current treatment pathways of 2461 people with treatment-resistant depression: mixed-methods study.The British journal of psychiatry : the journal of mental science · 2026Article
- Episode-wide Maudsley staging in treatment-resistant depression: a longitudinal tertiary-care comparison of dimensional and categorical outcomes.Frontiers in psychiatry · 2026Article
- Precision diagnosis model for treatment-resistant depression integrating serum metabolomics and clinical risk factors.Frontiers in psychiatry · 2026Article
- Article
- Understanding the Use of Atypical Antipsychotic Treatment for Major Depressive Disorder: An International Cross-Sectional Survey of Health Care Providers.Journal of clinical psychopharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the availability of effective therapies, many patients with major depressive disorder (MDD) develop treatment-resistant depression (TRD).
aimsTo evaluate and compare prescribing patterns, contact with specialist services and treatment outcomes in patients with MDD and TRD.
methodThis was a retrospective analysis of linked primary and secondary care National Health Service data in the north-west London Discover-NOW data-set. Eligible patients were adults who had diagnostic codes for depression and had been prescribed at least one antidepressant between 2015 and 2020.
resultsA total of 110 406 patients were included, comprising 101 333 (92%) with MDD and 9073 (8%) with TRD. Patients with TRD had significantly higher risks of suicidal behaviour and comorbidities such as anxiety, asthma, and alcohol or substance misuse (all
conclusionsThere appears to be a considerable difference between treatment guidelines for depression and TRD and the reality of clinical practice. Long-term treatment with single antidepressants, poor remission, and high relapse rates among patients in primary care highlight the need to optimise treatment pathways and access to newer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.